Literature DB >> 27570914

Meta-analysis of average symptom change in inpatient treatment for posttraumatic stress disorder in veteran and active duty U.S. military samples.

Justin S Campbell1, George H Loeffler1, Steven Pulos2, Annie W Campbell.   

Abstract

This study tested the hypothesis that inpatient/residential treatment for PTSD associated with military duty should result in significantly lower PTSD symptoms at patient discharge compared to patient intake. Meta-analysis of effects comparing intake and discharge PTSD symptoms from 26 samples, reported in 16 studies, supported this hypothesis (d = -.73; p < .00001). Moderator analysis indicated between-study variation in PTSD symptom changes was predominantly due to the type of measure used, with the Clinician Administered PTSD Scale producing the largest effect (d = -1.60). Larger effects were also observed for more recently published studies and studies with larger percentages of females. These findings support the efficacy of inpatient treatment for military PTSD, although a causal factor for effectiveness could not be identified. Further, the results indicate between-program comparisons of symptom reduction require the same measure of PTSD. (PsycINFO Database Record (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Year:  2016        PMID: 27570914     DOI: 10.1037/ser0000104

Source DB:  PubMed          Journal:  Psychol Serv        ISSN: 1541-1559


  2 in total

1.  Overcoming Adversity and Stress Injury Support (OASIS): Evaluation of Residential Treatment Outcomes for U.S. Service Members with Posttraumatic Stress Disorder.

Authors:  Kristen H Walter; Casey B Kohen; Cameron T McCabe; Jessica R Watrous; Justin S Campbell
Journal:  J Trauma Stress       Date:  2021-01-29

2.  Effectiveness of a Multimodal, Day Clinic Group-Based Treatment Program for Trauma-Related Disorders: Differential Therapy Outcome for Complex PTSD vs. Non-Complex Trauma-Related Disorders.

Authors:  Anke Philipps; Andrea Silbermann; Eva Morawa; Mark Stemmler; Yesim Erim
Journal:  Front Psychiatry       Date:  2019-11-07       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.